Skip to main content

Table 1 Laboratory and clinical data at baseline and six months (mean ± standard deviation) and statistical significance results

From: A feasibility study of mHealth and wearable technology in late onset GM2 gangliosidosis (Tay-Sachs and Sandhoff Disease)

  Baseline Month 6 Wilcoxon p-value
6MWT (meters) 316.88 ± 123.26 345.50 ± 117.68 0.11
BARS score 9.75 ± 6.09 10.06 ± 6.96 0.59
Neuroglyphics Off Target-dominant (%) 19.00 ± 14.11 16.62 ± 10.91 0.69
Neuroglyphics Off Target- Nd (%) 21.19 ± 13.99 17.77 ± 11.65 0.47
BARS Upper score 2.63 ± 2.22 2.75 ± 2.84 0.79
9HP Dom Avg (sec) 28.83 ± 8.23 27.22 ± 7.84 0.38
9HP Dom z-score (sec) 4.35 ± 2.77 4.04 ± 2.77 0.38
9HP Nd Avg (sec) 30.89 ± 15.88 29.84 ± 11.41 0.78
9HP Nd z-score (sec) 4.71 ± 5.39 5.05 ± 4.96 1
GAITRite data:
Cadence (steps/min) 94.33 ± 18.86 99.95 ± 13.88 0.15
Velocity (cm/sec) 97.86 ± 34.08 108.59 ± 33.61 0.15
Step Length (cm) 60.10 ± 12.74 63.68 ± 14.62 0.38
Step Width (cm) 11.72 ± 3.77 11.53 ± 3.46 0.55
Step Time (sec) 0.67 ± 0.15 0.61 ± 0.09 0.11
  1. Avg Average, BARS Brief Ataxia Rating Scale, cm Centimetres, DOM Dominate min Minute, 6MWT 6-min walk test, Nd Non-dominant, sec Seconds, 9HP 9-hole peg test – a brief, standardized and quantitative test of upper extremity (hand and arm) function z-score: calculated by converting raw into a common metric